Innovative Drug Development for Headache Disorders (Frontiers in Headache Research Series No. 16)
By: Nabih M. Ramadan (editor), Jes Olesen (editor)Hardback
1 - 2 weeks availability
Migraine treatment improved considerably with the advent of the 'triptans' in the 1990s. While the drugs used previously for headache treatment had efficacy, some compounds had bothersome side effects and their overuse could lead to severe complications. In the early days of the triptans, it was widely presumed that migraine was no longer a treatment problem. However, it has gradually been recognized that a significant proportion of patients are not responsive to triptans or do not tolerate them. It is now clear that, even with effective treatment, patients with frequent migraine attacks are not treated well exclusively with acute medications. This is partly because patients are still bothered by the attacks and partly because frequent intake of acute medication may result in medication-overuse headache. These problems have led to a renewed interest in preventive migraine drugs.
Part of the Frontiers in Headache Research series, this book summarizes the several promising new avenues for the development of future drugs for the treatment of migraine, including cortical-spreading depression inhibition, nitric oxide synthase inhibition and calcitonin gene-related peptide (CGRP) receptor antagonism, as well as other potential targets. The book presents frontline knowledge of these evolving modalities as far as it is available in the public domain. It is hoped that readers and their patients will find it exciting to learn about all the novel possibilities, and also that the impressive research advances in migraine will lead to increased funding, not only of migraine but also of other types of headache.
SCREENING MODELS ; 1. The human GABA transporter GAT-2 - From cloning to high throughput screening ; 2. Low throughput preclinical models for headache ; 3. Human models - screening models ; TRIALS METHODOLOGY ; 4. Stricter success criteria, qualitative and quantitative end points: Acute vs. prevention trials ; 5. Health related quality of life and similar end points ; 6. Clinically relevant designs and outcome measures for acute migraine trials ; 7. Effectiveness of different steroid dosage in Tolosa-Hunt syndrome with different phenotypes: some critical points about the new HIS classification ; 8. Discussion summary: Trials methodology ; NO AND SPREADING DEPRESSION MODULATORS ; 9. Inducible nitric oxide synthase and development of new migraine treatments ; 10. Mechanisms of cortical spreading depression as targets for migraine therapy ; 11. Tonabersat ; 12. Discussion Summary: NO and spreading depression modulators ; CGRP AND 5-HT MODULATORS ; 13. Calcitonin gene-related peptide (CGRP): relevance for migraine ; 14. New 5-HT related drug targets ; 15. Effect of two novel CGRP-binding compounds in a closed cranial window rat model ; 16. Vasoactive intestinal polypeptide is unlikely to be a target for headache and migraine treatment ; 17. Discussion Summary: CGRP and 5-HT modulators ; ION CHANNEL MODULATORS AND ANTIEPILEPTICS ; 18. Migraine: from genes to pathophysiology - transgenic mouse models of migraine ; 19. Katp channels and migraine ; 20. Antiepileptic drugs and migraine ; 21. Discussion Summary: Ion channel modulators and antiepileptics ; OTHER FUTURE TARGETS FOR HEADACHE THERAPY ; 22. Innovative drug development for headache disorders - Glutamate ; 23. The modulation of TRPV1 channels by cannabinoid1 receptors ; 24. Future targets for headache therapy: Prostanoids ; 25. Role of anandamide in the modulation of nitroglycerin-induced hyperalgesia - a study in the rat
Number Of Pages:
- ID: 9780199552764
- Saver Delivery: Yes
- 1st Class Delivery: Yes
- Courier Delivery: Yes
- Store Delivery: Yes
Prices are for internet purchases only. Prices and availability in WHSmith Stores may vary significantly
© Copyright 2013 - 2017 WHSmith and its suppliers.
WHSmith High Street Limited Greenbridge Road, Swindon, Wiltshire, United Kingdom, SN3 3LD, VAT GB238 5548 36